$1.15
5.74% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US92941V1008
Symbol
VYNE
Sector
Industry

VYNE Therapeutics Inc Stock price

$1.15
-0.64 35.75% 1M
-1.67 59.22% 6M
-2.20 65.67% YTD
-1.58 57.88% 1Y
-6.05 84.03% 3Y
-140.33 99.19% 5Y
-2,065.97 99.94% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.07 5.74%
ISIN
US92941V1008
Symbol
VYNE
Sector
Industry

Key metrics

Market capitalization $19.16m
Enterprise Value $-42.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.24
EV/Sales (TTM) EV/Sales -84.52
P/S ratio (TTM) P/S ratio 38.32
P/B ratio (TTM) P/B ratio 0.33
Revenue growth (TTM) Revenue growth 18.16%
Revenue (TTM) Revenue $500.00k
EBIT (operating result TTM) EBIT $-43.64m
Free Cash Flow (TTM) Free Cash Flow $-34.09m
Cash position $61.52m
EPS (TTM) EPS $-0.93
P/E forward negative
P/S forward 27.37
EV/Sales forward negative
Short interest 1.45%
Show more

Is VYNE Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

VYNE Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a VYNE Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a VYNE Therapeutics Inc forecast:

Buy
100%

Financial data from VYNE Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.50 0.50
19% 19%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
1% 1%
2,636%
- Research and Development Expense 31 31
90% 90%
6,190%
-44 -44
49% 49%
-8,726%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -44 -44
49% 49%
-8,727%
Net Profit -40 -40
40% 40%
-7,964%

In millions USD.

Don't miss a Thing! We will send you all news about VYNE Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VYNE Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet...
Neutral
GlobeNewsWire
26 days ago
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company's Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis. The clinical hold determination was made foll...
Neutral
GlobeNewsWire
2 months ago
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune mediated conditions with high unmet need, today announced that VYNE's management will participate in the H.C. Wainwright 3rd Annual Autoimmune & In...
More VYNE Therapeutics Inc News

Company Profile

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

Head office United States
CEO David Domzalski
Employees 13
Founded 2011
Website www.vynetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today